Business Wire

THALES

9.6.2020 08:02:10 CEST | Business Wire | Press release

Share
European Organisations Have False Sense of (cyber) Security, Despite Over Half Suffering a Breach

New insights from the 2020 Thales Data Threat Report – European Edition reveal that European organisations have a false sense of security when it comes to protecting themselves, with only two-thirds (68%) seeing themselves as vulnerable, down from nine in ten (86%) in 2018. This confidence flies in the face of the findings of the survey of 509 European executives which reveals over half (52%) of organisations were breached or failed a compliance audit in 2019, raising concerns as to why a fifth (20%) intend to reduce data security spend in the next year. The findings come as workers across Europe are working from home due to COVID-19, often using personal devices which don’t have the built-in security office systems do, significantly increasing risk to sensitive data.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200608005431/en/

Thales will host a webinar, “Data Security Threats and Trends in Europe” on 16 June to discuss the report in more detail. To join, please visit the registration page .

Across the board, companies are racing to digitally transform and move more applications and data to the cloud; two-fifths (37%) of European countries stated they are aggressively disrupting the markets they participate in or embedding digital capabilities to enable greater enterprise agility. A key aspect of this transformation is in the cloud becoming the leading data environment. Nearly half (46%) of all data stored by European organisations is now stored in the cloud, and with 43% of that data in the cloud being described as sensitive, it is essential that it is kept safe.

As more sensitive data is stored in cloud environments, however, data security risks increase. This is of particular concern given that 100% of businesses surveyed report that at least some of the sensitive data they are storing in the cloud is not encrypted. Only 54% of sensitive data in the cloud is protected by encryption and even less (44%) is protected by tokenisation, highlighting the disconnect between the level of investment companies are making into cybersecurity and the increasing threats they face.

Multi-Cloud Adoption Complicates Data Security

Despite the multitude of threats, businesses feel that the complexity (40%) of their environments is holding their data security capabilities back. Multi-cloud adoption is the main driver of this complexity; four-fifths (80%) of businesses are using more than one IaaS (Infrastructure as a Service) vendor, whilst a third (29%) have more than 50 SaaS (Software as a Service) applications to manage. Businesses also identified a lack of budget (30%), staff to manage (28%) and organisation buy-in/low priority (25%) as other top blockers.

“Businesses are continuing to race towards digital transformation and many are increasingly reliant on complex cloud environments, without taking a zero-trust approach. Data is more at risk than ever, whilst organisations are unwittingly creating the perfect storm for hackers by not implementing the security basics,” commented Rob Elliss, EMEA Vice President for Data Security solutions at Thales . “Unfortunately, this will result in increasing problems, particularly in a world where working remotely will be part of the new-normal, unless companies can step up to the plate when it comes to keeping data safe.”

Quantum(fying) the problem

Whilst organisations continue to look at the threat of today, many are starting to turn their attention to peril that the acceleration of computing power, quantum, could bring to them. In fact, almost all (93%) respondents are concerned quantum computing will lead to exploits being created that could expose the sensitive data they hold. What’s more, seven in 10 (69%) European organisations expect quantum to affect their cryptographic operations in the next five years.

As a result, most organisations are reacting, with a third (31%) planning to offset quantum computing threats by switching away from static encryption or symmetric cryptography. Furthermore, a similar amount (30%) plans to implement key management that supports quantum safe random number generator.

“It is clear that businesses are aware of evolving threats they face and it’s reassuring to see them acknowledging some of the key steps they need to take – including moving away from static encryption and implementing quantum-proof key management. It’s critical, though, that organisations don’t just look at threats years away, but invest in their cybersecurity processes now and see it as an integral part of their digital transformation,” Elliss concluded .

About Thales

Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 83,000 employees in 68 countries, Thales generated sales of €19 billion in 2019 (on a pro forma basis including Gemalto over 12 months).
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments.

PLEASE VISIT

Thales Group
Market page
Download HD photos

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye